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STDs and HIV/AIDS

Role of Raltegravir in HIV-I Management
Kristina EE Rokas, P Brandon Bookstaver, Caitlin L Shamroe, S Scott Sutton, Vanessa E Millisor,
Jacquelyn E Bryant, and Sharon B Weissman

I

n the era of potentantiretrovira1 (ARV)
therapy(ART), Hlv-I infection has become a chronicdiseaserather than a terminal illness, allowing those whoaretreated with ART to have normal life expectancies} Complications, mortality, and
viral transmission of Hlv-I have significantly decreased with the adventof new
ARVs.2.7 Long-term adverse effects of
olderARVs include dysglycemia, dyslipidemia, lipodystrophy, and gastrointestinal
discomfort' If nonadherence occurs in patients on ART, Hlv-l drugresistance may
develop,limiting the effectiveness of future therapy. Hence, it is crucial to choose
regimens that are not only effective
against Hl'V-l , but alsominimize adverse
events andmaximize adherence.
Raltegravir,formerly known as MK0518, is the first integrase strandtransfer
inhibitor (INSTI) to be approved by the
Food and Drug Administration (FDA). It
works by preventing the formation of a
functional integrated proviral DNA.s
First approved in October 2007 for salvage therapy in ARV-experienced patients, raltegravir is active against multiclass-resistant HIV-I and both CCR5tropic and CXCR4-tropic HIV_I.s-lo In
December 2011, the FDA extended the

To review the literature concerning the role of raltegravir in the
treatment of HIV·1 in antiretroviral (ARV)-experienced and ARV-na"ive patients.

OBJECTIVE:

DATA SOURCES: A PubMed search was conducted for published data through
March 2012 using the search terms raltegravir, MK-0518, and integrase strand
transfer inhibitor. An additional search of International Pharmaceutical Abstracts
for unpublished data, including data from the Infectious Diseases Society of
America, the Conference on Retroviruses and Opportunistic Infections, the
International AIDS Society. and the Interscience Conference on Antimicrobial
Agents and Chemotherapy, was conducted using similar search terms.
STUDY SELECT10N AM) DATA EXmACTlON: In vitroand in vivo Phase2, Phase 3 , and
postmarketing studies availableIn English, evaluating antiretroviral regimens that
containrattegravir for the treatment of HIV·1 infection in both ARV·naive and ARV·
experienced patients, were evaluated. Studies assessing raltegravirpharrnacokineticsand pharmacodynamics were included for review.
DATA SYNTliESlS: The nucleoside-based regimen of raltegravir with tenofovir/emtri·
citabine provides an effective first·line treatment option. However, nucleoside·
sparing regimens appear unfavorable in ARV·naive subjects and should be
reserved for patients with limited treatment options. Raltegravir used with optimized
background therapy provides an a1temative regimen for ARV-experienced patients.
This review describesthe available in vitro and in vivo data on raltegravir potency,
defined as the abilityto achieve undetectable viral load, and safety profile, as well
as comparison to standardHIV·1 therapies.

Raltegravir has demonstrated potent antiretroviral activity against
HIV·1 in both ARV·naive and ARV-experienced subjects, with the benefits of a
favorable adverse effect profile and minimal drug interactions. Raltegravir must
be dosed twice daily, as once daily raltegravir displays decreased virologic
eUicacy compared to twice daily dosing. However, the ongoing development of
new integrase strand transferinhibitors may provide potent once daily regimens.

CONCLUSIONS:

KEY WORDS: antiretroviralthe rapy, integrase strand transfer inhibitor, MK-0518,
raltegravir, treatment naive.
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indication of raltegravir to childrenand adolescents ages 218 with IllV-1, providing adolescents a new therapy option
with a unique mechanism of action against HIV-1.8 In
2009, the FDA expanded raltegravir's approval for firstline treatment of ARV-naIve HIV-1 patients.'
When given with 2 nucleoside reverse transcriptaseinhibitors (NRTIs), raltegravir showspotentviralsuppression,
with a favorable adverse effect profile and minimaldrug interactions.l':" The success of raltegravir has led to the development of second-generation INSTIs.Is.21 This article explores the role of raltegravir in therapy among ARV-naIve
andARV-experienced patients.
Data Sources and Selection

A PubMed search was conducted for published data
through March 2012 using the search terms raltegravir,
MK-0518, and integrase strand transfer inhibitor. An additional search of International Pharmaceutical Abstracts
for unpublished data, including data from the Infectious
Diseases Society of America, the Conference on Retroviruses and Opportunistic Infections, the International
AIDS Society (lAS), and the lnterscience Conference on
Antimicrobial Agents and Chemotherapy, was conducted.
In vitro and in vivo Phase 2, Phase 3, and postmarketing
studies availablein English, evaluating antiretroviral regimens that contain raltegravir for the treatment of HIV-1
infection in both ARV-na'ive and ARV-experienced patients, were evaluated. Studies assessing raltegravir pharmacokinetics and pharmacodynamics were included for
review.

PHARMACOKINETICS

Raltegravir absorption is rapid, with a time to reach
maximum concentration of 3 hours,"There is a linear increase in the area under the curve (AUC), and the 12hour trough concentration (C12) of raltegravir is proportional to the dose when given orally in single doses of
100-800 mg," The Cl2ranges from 70.6 to 300.8 nM and
the AUCo.12h ranges from 6.53 to 45.27 jlM.h in this dose
range." Although the fat content of meals creates variability in raltegravir absorption,the variability is not clinically significant. Raltegravir may be administered without regard to meals," Protein binding of raltegravir is
83%. Volume of distribution in animal studies ranges
from 0.4 to 2 Llkg.8,23
Raltegravirdistributes primarilyin the plasma, gastrointestinal tract, and organs of excretion,with significant penetrationinto the cervicovaginal and seminalfluids.23•26 Raltegravir concentrations in these compartments exceed'the
95% inhibitory concentration (IC ) of wild-type HIV_1.24•27
Raltegravir concentrations in the central nervous system
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PHARMACODYNAMICS

Multipledoses of raltegravir, at 100 mg or greaterevery
12 hours, achieved a C12 >33 nM (14.6 ng/mL), the target
trough concentration to reach the IC9s for HIV-1 in vitro in
50% human serum.22,23 Raltegravirwas generallywell-tolerated at doses up to 1600 rug/day." Tolerabilityand efficacy have been observedregardless of race or sex," Raltegravir has a low rate of virologic failurewhen dosed at 400
mg or greater every 12 hours and has demonstrated rapid
antiviral activity with a mean viral load reduction of 1.66
log., copies/mL by day 10.8 The threshold C12 correlating
with reducedefficacy has not yet been identified.
ONCE DAILY VSlWlCE DAILY DOSING

Pharmacokinetics and Pharmacodynamics

9s

remain above the 50% inhibitoryconcentration (ICso) , but
can exceed the IC9s for wild-type IllV-1 in 52% (13/25) of
cerebrospinal fluid (CSF) specimens.V" Dose intensification in virally suppressed patients has not been found to
further decrease either intrathecal immunoactivation or
CSF HIV-1 RNA.30
Raltegravir is metabolized through glucuronidationvia
UGTlA1, which resultsin the formation of raltegravir-glucuronide," Obesity has not been shown to significantly influence phase II metabolic reactions.t'-"Currently, it is unknown if dose adjustmentsare needed based on weight or
body mass index. The average terminal half-life of raltegravir is 9 hours, reaching steady-state concentrations in 2
days.8,22 Following oral twice daily dosing, 51% and 32%
of raltegravir is excretedin the feces and urine, respectively.8,22

The FDA-approveddose of raltegravir is 400 mg twice
daily. Dose adjustments are not required for renal or mildto-moderate hepatic impairment.v" Raltegravir has not
been evaluated in severe hepatic impairment," Since raltegravir binds to the integration complex for approximately
27 hours, once daily dosing (800 mg) was hypothesized to
be as efficacious as twice daily dosing (400 mg).35,36
The ODIS trial evaluated subjects who switchedfrom a
proteaseinhibitor (Plj-based regimento raltegravir 800 mg
once daily or 400 mg twice daily." The study was stopped
prematurely at 24 weekswith data collected in 222 subjects,
due to unfavorable antiviral efficacy observed withonce daily raltegravir. Failureoccurredin 6.4% (12/187) of patients
receiving once dailyraltegravir comparedto 2.9% (1/35)of
thosereceiving twicedailytreatment (p = 0.18).The QDMRK trial assigned 770 ARV-naIve subjects to receive once
dailyor twicedailyraltegravir withtenofovir/emtricitabine."
More subjects in the twice daily regimen achieved HIV-1
RNA levels<50 copies/mL (p = 0.044),with the once daily
regimen displaying inferiority to the twicedailyregimen. At
48 weeks,virologic failure occurred in 14% (53/382) of sub-
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jects in the oncedailyarm compared to 9% (35/388) of subjectsin the twicedaily arm.
The QDMRK trial demonstrated that twice daily dosing
in ARV-na'ive patients must be utilized because of inferior
virologic efficacyand increasing resistance seen with once
daily dosing," Because raltegravir remains unaffected by
the cytochrome P450 system, it does not have a pharmacokineticbooster agent and thereforeis unlikelyto ever be
utilizedas a once daily regimen.

tricitabine in 566 ARV-na'ive HIV-l infected subjects.v"
The raltegravir arm achieved time to viral suppression
soonerthan the efavirenzarm (p < 0.0001).11 At 48 weeks,
noninferiority was demonstrated (p < 0.0001) and maintained through 156 weeks,":" At 156 weeks, 75.4%
(212/281) of subjects in the raltegravir arm and 68.1 %
(192/282) in the efavirenz arm achieved HIV-l RNA levels <50 copies/mL(p < 0.001; 95% CI -0.2 to 14.7).41 The
raltegravir arm demonstrated significantly higher increases
in CD4 count from baseline. Mean changes from baseline
CD4 count were 331.7 cells/rum' in the raltegravir arm
versus295.2cells/mm' in the efavirenzarm (95% CI 3.9 to
69.2). Overall,approximately 2.5% (7/281) of subjects developed resistance to raltegravir and 3.5% (10/282) to
efavirenz. The 96-week data of the STARTMRK trial led
to the FDA approval of raltegravir in ARV-na'ive patients,
as well as to the change in guidelines to includeraltegravir
on the preferred list.2.l 9 The QDMRK trial confirms that
raltegravir 400 mg twice daily plus tenofovir/emtricitabine
is an effective initialtherapyfor HIV-l.38
Raltegravir in combination with abacavir/lamivudine
was evaluated in the SHIELD trial." This was a noncomparative trial in which 35 ARV-na'ive subjects were initiated on raltegravir with abacavir/lamivudine.At 96 weeks,
raltegravirplus abacavir/lamivudine displayed potent suppressionof the virus, with 77% (27/35)of subjectsachieving undetectable viral loads <50 copies/mL.
The potency and durability of raltegravir against HIV-l
in ARV-na'ive 'subjects supportits role in current guidelines
as a preferred agent.2.l 9 Raltegravir may be particularly

Role In ARV·Naive Patients
Raltegravir is listed as a preferred agent for ARV-na'ive
patientsin both the Departmentof Health and Human Services (DHHS)and lAS guidelines.P? Raltegravir should be
used with other ART,preferably the dual NRTI combination tenofovir/emtricitabine (AI recommendationj.' Abacavir/lamivudine with raltegraviris an alternativeregimen
if tenofovir/emtricitabine is contraindicated (BIII recommendation)," Table 1 summarizes data from clinical trials
evaluating raltegravirwith dual NRTIs in ARV-na'ive subjects.13,14,38,40,41
Gotuzzo et al. comparedraltegravir to efavirenzin combination with tenofovir/lamivudine in ARV-nai've subjects}4,40 At 240 weeks, 69% (110/160) in the raltegravir
arm and 63% (24/38)in the efavirenzarm achievedHIV-l
RNA levels <50 copies/ml.." Results from this study
demonstrate safetyand efficacyof an INSTI with dual NRTIs in ARV-na'ive subjects through5 years.
In the multinational STARTMRKtrial, raltegravir was
compared to efavirenz in combination with tenofovir/em-

Table 1. Clinical T ria l Data of Raltegravir w ith Dual Nucleosides in Antiretroviral-Na'ive Subjects
Reference

Trial

Reg imen

Out com es

Adverse Even ts

Markow itz
(2007)14 and
Gotuzzo
(2011)40

PROTOCOL
004

RAL + TDFI3TC
vs EFV +
TDFI3TC

96 weeks: 84.2% (32138) in EFV arm and 83.1%
(133/ 160) in RAL arm had HIV-l RNA <50 copieslmL
240 weeks: 72% (115/160) in RAL arm and 66%
(25138 ) in EFV arm had HIV-l RNA <400 copieslmL

RAL arm at 240 weeks : nausea 12.5%
(20/160) , dizziness 8.8% (14/160) ,
headache 8.1% (13/160) , insomnia
8.1% (13/160) , creatine kinase
~10 ULN 9.4% (15/160)

Rockstroh
(2011)41

STARTMRK

RAL + TDF/FTC
vs EFV+
TDFIFTC

48 weeks : 86 .1% (241/280) in RAL arm and 81.9%
(2301281) in EFV arm had HIV-1 RNA <50 copieslmL
(p <0.000 1)
96 weeks: 81% (2281281) In RAL arm and 79%
(2231282) in EFV arm had HIV·l RNA <50 copieslmL
(p<O.OOl)

156 weeks : fewer drug·related clinical
adverse events occurred In RAL arm
(49% vs 80%; p < 0.001) ; elevations
in fasting lipid levels were lower In the
RAL arm (p < 0.005)

Eron (2011)38

QDMRK

RAL + TDF /FTC'

48 weeks : 83.2% (3181382) in once-da ily group and
88.9% (3431386) in twice-daily group had HIV·l RNA
<50 copieslmL (p 0.044)

4B weeks : serious adverse events in 7%
(261382) of once-daily arm and 10%
(401388) of twice-daily arm

RAL + ABCI3TC

48 weeks : 91% (32135) had HIV-l RNA <50 copieslmL
96 weeks : 80% (28135 ) and rr« (27/35) had HIV-l
RNA <400 and <50 copleslmL, respectively

96 weeks : any treatment-related grade
2·4 adverse eHect17% (6/35) ; any
grade 3-4 laboratory test abnormality
26% (9/35); median lipid Increases
from baseline: TG 25 mg/dL , LDL
11 mg/dL, HDL 6 mgldL, TC 28 mg/dL

=

Young (2011)13 SHIELD

.-

=

=

=

=

=

3TC lamivudine; ABC abacavir; EFV efavirenz; FTC emtricitabine; HDL high-dens ity lipoprotein; LDL
tegrav ir; TC total cholesterol ; TDF tenofov ir; TG Iriglycerides ; ULN upper limit of normal.
ORAL 400 mg twice daily vs 800 mg once daily.

=

=

=

=
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beneficial when the use of a nonnucleoside reverse transcriptase inhibitor (NNRTI)- or PI-based regimen is less
favorable. Some clinicians consider raltegravir less appealing for initial therapy because of its twice daily dosing and
its cost compared to other preferred ARV-na'ive regimens.
Although these concerns are important for clinicians to
consider prior to the initiation of raltegravir, new long-term
safety and efficacy data demonstrate that raltegravir is a
valuable first-Iine therapy for ARV-na'ive patients.
NRTI·SPARING STUDIES

Investigators have been interested in using raltegravir
with a PI as part of a nucleoside-sparing regimen, avoiding
toxicities associated with NRTIs. Table 2 summarizes data
from clinical trials evaluating raltegravir in nucleosidesparing regimens in ARV-nai've subjects.42•47 Raltegravir
with ritonavir-boosted darunavir is a regimen of particular
interest. In the ACTG A5262 study, 112 ARV-na'ive subjects received darunavir 800 mg once daily plus ritonavir
100 mg once daily plus raltegravir 400 mg twice daily," At
48 weeks, 61% (69/113) of subjects achieved Hlv-I RNA
<50 copies/mL, and virologic failure occurred in 28 subjects. Of those available for resistance testing, 5 of 25 subjects developed integrase mutations. An elevated baseline
Hl V-I RNA >100,000 copies/mL was associated with an
increased likelihood of developing raltegravir resistance
and virologic failure. Previous pharmacokinetic data have

suggested that raltegravir and darunavir plus ritonavir may
lower plasma concentrations of darunavir." However,
darunavir plasma concentrations in this study" were comparable to the concentrations reported by Boffito et al.49 in
a pharmacokinetic study of healthy volunteers utilizing the
same doses.
In the 48-week RADAR study, darunavir 800 mg plus
ritonavir 100 mg once daily was used with raltegravir 400
mg twice daily or tenofovir/emtricitabine 300 mg/200 mg
once daily," At 24 weeks, 86.2% (25/29) of subjects in the
raltegravir arm and 87.9% (29/33) in the tenofovir/emtricitabine arm achieved HIV-l RNA <48 copies/mL (p =
0.570). The final 48-week analysis of the RADAR study is
ongoing, but the study lacks sufficient power. The ANRS
143/NEAT 001 study is an ongoing, open-label, randomized control trial assessing the nucleoside-sparing regimen
of raltegravir with darunavir plus ritonavir, and is estimated to enroll 800 subjects." Thus, data from the ANRS
143/NEAT 001 study are warranted.
The 96-week PROGRESS study compared raltegravir
400 mg twice daily plus lopinavir/ritonavir 400 mg/IOO
mg twice daily to the 3-drug regimen of tenofovir/emtricitabine 300 mg/200 mg once daily plus ritonavir-boosted
lopinavir 400 mg/IOO mg twice daily in ARV-na'ive subjects.44,45 At 48 weeks, the raltegravir-based regimen displayed noninferiority to the 3-drug regimen, and at 96
weeks, both arms displayed similar rates of virologic suppression (p = 0.767). The small, pilot CCTG 589 study

Table 2. Clinical Trial Data of Raltegravir witha Nucleoside-Sparing Regimen in Antiretroviral-Na'ive Subjects
Tri al

Regimen

Taiwo
(2011)42

ACTGA5262

RAL + DRV/RTV

24 weeks: 74% (84/113 ) had HIV-1 RNA <50
copies/mL
48 weeks : 61% (69/113) had HIV-1 RNA <50
copies/mL

48 weeks: no adverse events considered
probably or definitely due to RAL treatment

Bedimo
(2011)43

RADAR

RAL + DRV/RTV
vsDRV/RTV +
TDF/FTC

24 weeks : 86.2% (25/29) In RAL arm and 87.9%
(29/33) in TDFIFTC arm had HIV-1 RNA <48
copies/mL (p = 0.570)

RAL arm at 48 week s: severe adverse events
7.7% (3/39) ; mean lipid changes from
baseline: TC 21.6 mg/dL , TG - 7 mg/dL

Reynes
PROGRESS
(2011)44.45

RAL + LPV/RTV
vs LPV/RTV +
TDF/FTC

48 weeks : 83.2% (84/101) in RAL arm and 84.8%
(89/105) in TDF/FTC arm had HIV-1 RNA
<40 coples/mL
96 weeks : 66% (67/101) in RAL arm and 69%
(72/105) in TDF/FTC arm had HIV·1 RNA
<40 copieslmL

96 weeks: occurrence of treatment-emergent
mod erate-to-sever e drug -related adverse
events similar between both arms

Bowman
(2011)4&

CCTG 589

RAL + LPV/RTV
vs
EFVITDF/FTC

4 weeks : 54% in RAL arm and 12% in EFV arm
had HIV·1 RNA <50 cop leslmL (p = 0.003)
48 weeks : 69% (18/26) in RAL arm and 84%
(21/25) In EFV arm had HIV-1 RNA <50 copieslmL

RAL arm at 48 weeks: gastro intestinal
(14/26) , rash (3126). central nervous system
(3/26) ; median lipid changes from baseline :
TC 31 mg/dL (p = 0.2), TG 26 mg/dL
(p=0.2)

Kozal
(2010)47

SPARTAN

RAL+ATV a

24 weeks: 82.5% (52/63) had HIV-1 RNA
<400 copieslmL

24 weeks: RAL + ATV AEs included : grade 4
laboratory elevations in bilirubins 13/63
(20.6%), of which 12/63 (19.0%) were clinical
events

Reference

=

AEs = advers e events ; ATV atazanavir; DRV
avir; TC total cholesterol ; TDF tenofovir ; TG
aATV300 mg twice daily.

=
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=

Out co mes

Adverse Even ts

=darun avir; EFV =elavirenz; FTC =emtricitabine; LPV =lopinavir; RAL =raitegra vir; RTV =riton=triglyceride.
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=

compared raltegravir plus ritonavir-boosted lopinavir (n
26) to efavirenzltenofovir/emtricitabine (n = 25) in ARVnaive subjects." Initial time to viral suppression was significantly faster for the raltegravir arm (p 0.003), but at
48 weeks, similar suppression was observed between the 2
arms. These trials suggest that raltegravir with lopinavir/ritonavir may be an effective nucleoside-sparing regimen,
but clinicians should use caution, as these studies were limited by a small sample size.
In the SPARTAN study, the safety and efficacy of raltegravir 400 mg twice daily plus atazanavir 300 mg twice
daily was assessed in ARV-naive subjects .47 The dose of
atazanavir utilized was not FDA approved and spared the
ritonavir booster. By 24 weeks, 74.6% (47/63) of subjects
achieved HIV-I RNA <50 copies/mL, consistent with current standards of care. Of the subjects available for resistance testing, 57.1 % (417) of subjects developed raltegravir
resistance, approximately 6.3% (4/63) overall. Clinicians
should employ caution with raltegravir plus atazanavir regimens until long-term data assessing the combination are
available.
Previous studies using raltegravir with dual nucleosides
in ARV-naive subjects have shown minimal drug resistance. In contrast, these nucleoside-sparing studies suggest
that raltegravir resistance may occur more frequently when
used with a nucleoside-sparing regimen.38. 47 The nucleoside-sparing regimen with the most positive data is ralte-

=

gravir plus lopinavir/ritonavir; however, this regimen has
fallen out of favor due to increased toxicity when compared to other PIs, such as atazanavir or darunavir. Nucleoside-sparing regimens containing raltegravir are not endorsed by guidelines and should be reserved for patients
unable to take other regimens.

Role in Antiretroviral-Experienced Patients
In heavily pretreated patients, the selection of active ART
is limiteddue to resistance," To date there is littleINSTI resistance in raltegravir-naive patients." Raltegravir has been
shown to have an additive effect to optimized background
therapy (OBT) , demonstrating greater absolute response
rates than OBT alone. I0,52,53 The background therapy is
generally chosen at the clinician's discretion, based on previous ART and results of available resistance tests.52 Table
3 summarizes data from clinical trials evaluating raltegravir in ARV-experienced subjects,53.58
In the BENCHMRK 1 and 2 trials, the basis for initial
FDA approval in ARV-experienced patients , raltegravir
was compared to placebo when added to OBT in highly
pretreated individuals.P-" At 96 weeks, 57% (266/466)
of subjects in the raltegravir group versus 26% (62/237)
of subjects in the placebo group had an undetectable viral load." Raltegravir-treated individuals had significantly greater decreases in mean HIV-l RNA levels and in-

Table 3. Clinical Trial Data of Raltegravir in Antiretroviral-Experienced SUbjects
Reference

Out co mes

Trial

Regi men

Steigbigel
(20 10)53

BENCHMRK 1
and 2

RAL + OBT vs placebo
+OBT

96 weeks: 57% (2661466) in RAL arm vs 96 weeks: frequencies of adverse events
26% (62/237) in placebo arm had HIV·1 similar in both arms ; creat ine kinase
RNA <50 copieslmL ; RAL arm had
elevations slightly more common in RAL
significantly greater mean changes in
arm
CD4 cell counts (123 vs 49 cellslmm 3)

Towner
(2009)51

CHEER

LPVIRTV + 2 NRTls or
NNRTls in OBT vs RAL
+ 2 NRTls or NNRTls
in OBT

24 weeks : 49152RAL subjects with HIV-1
RNA below limit of quant ificat ion; mean
CD4 cell increase of 32 cellslmm3

RAL arm at 24 weeks : gastroenteritis (2/52)
and grade 2 liver enzyme abnormalities
(8152)

Gallien
(2011)5oC

EASIER-ARNS
138

RAL·b ased regimen

48 weeks: 90% (1531170) of subjects had
HIV-1 RNA <50 copieslmL; 1 subject
developed virologic failure

48 weeks : adverse effects similar in both
treatment arms ; grade 3·4 transam inase
elevation occu rred in 71170 subjects

LPVIRTV + 2 NRTls or
NNRTls in OBT vs RAL
+ 2 NRTls or NNRTls
In OBT

24 weeks : 84.4% (2931347) in RAL arm
and 90.6% (3191352 ) in LPVIRTV arm
had HIV·1 RNA <50 copieslmL

24 weeks: 6f35O subjects discontinued RAL

RTV·boost ed PI·based
therapy vs RAL-based
therapy

48 weeks : 89.2% (1241139) in RAL arm
and 86.6% (116/134) in RTV-boosted
Pl-based arm were free of treatment
failure

48 weeks: adverse events similar in both
treatment arms ; incidence of grade 3·4
adverse events significantly lower in the
RALarm

Eron (20 10)" SWITCHMRK
1 and 2

.

Martinez
(20 10)511

SPIRAL

Nguyen
(20 11)57

SWITCH·ER

EFV
OBT

RAL + EFV and NRTI
4 weeks : 22/53 subjects prefe rred RAL;
backbone (RAL) vs EFV
12/53 subjects preferred EFV; 19
+ RAL and NRTI
- subjeC1s had no preference
backbone (EFV)

Adverse Events

RAL arm at 4 weeks: events included
pulmonary embolism (1153)

=efavirenz ; LPV =lopinavir; NNRTI =nonnucleoside reverse transcriptase inhibitor; NRT! =nucleosidelnuc leotide reverse transcriptase inhibitor;
=optimized background therapy ; PI =protease inhibitor; RAL =raltegrav ir; RTV =ritonavir.
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creases in CD4 counts compared to those receiving
placebo. Additionally, subjects in the BENCHMRK trials with viral isolates possessing sensitivity to at least 2
drugs in their OBT demonstrated a greater response to
raltegravir. It is important that clinicians consider the activity of a patient's OBT against HIV-1 before initiating
raltegravir.
In the Gatell et al. study, efficacy was demonstrated
when raltegravirwas given to subjectsinfectedwith multidrug-resistant virus who also lacked active ART in their
OBT.lO Despite these findings, functional monotherapy
withraltegravir shouldbe avoided, as it results in lower response rates and a greaterrisk for the development of resistance. Raltegravir has also demonstrated efficacy when included in OBT for newer agents, including etravirine, in
ARV-experienced subjects." Based upon these findings,
raltegravir is an effective treatmentoption in ARV-experienced patients and should be limitedto heavilypretreated
patients with few remaining options.9,l0,53
SWITCH STUDIES

Several studies have investigated switching patients
from a suppressive ART regimen to a raltegravir-based
regimento minimizetoxicities or inconveniences of other
agents. The greatest success with switch studies has been
with switching from enfuvirtide to raltegravir. Enfuvirtide
has several limitations, including a need for twice daily
subcutaneous injections,resultingin painful injection site
reactions, and treatment fatigue. 58,60 The CHEER trialevaluated 52 ARV-experienced subjectspreviouslycontrolled
on enfuvirtide who were switched to raltegravir while
OBT remained unchanged," Forty-nine subjects met the
primary endpoint,HIV-1 RNA level <50 or 75 copies/mL
depending on the assayused,demonstrating efficacy of the
therapeutic switch.The EASIER-ANRS 138 trial evaluated the safety and efficacy of switching enfuvirtide to raltegravir in a population with multidrug-resistant HIV-1 and
HIV-1 RNA levels<400 copies/mL.54,60 The health-related
quality of life scores, measured by a self-administered
questionnaire, were morefavorable in the raltegravir arm/"
The EASIER-ANRS 138 trial also demonstrated noninferiority of the switch to raltegravir from enfuvirtide when
the primary clinical endpoint, virologic failure, was analyzed.54,60 Given the proven safety and efficacyof switching patients' therapy to raltegravir, combinedwith the improvedhealth-related quality of life and treatment tolerability,the data supporta benefitto proactively changing these
patients' therapy from enfuvirtide to raltegravir to help reduceadverse effects. and treatment fatigue.54,58,60
The safety and efficacyof switchingfrom a PI-boosted
regimen to raltegravir in order to simplify treatmentregimens and decrease potential adverse effects have been
theannals.com

evaluated.55,56,61 Two Phase 3 randomized controlled trials,
the SWITCHMRK 1 and 2, evaluated switching to raltegravir from a ritonavir-boosted lopinavir regimen." In
these studies,eligible subjects must have had documented
HIV-1 RNA concentrations <50 copies/mL for at least 3
months while on a lopinavir/ritonavir-based regimen with
2 NRTls or NNRTIs. Subjectswere randomizedto switch
to raltegravir or to remain on lopinavir/ritonavir while
OBT remained the same. The results of SWITCHMRK 1
and 2 showed that switchingto raltegravirwas associated
with greater reductions in serum lipid concentrations.
However, the studies were stopped at 24 weeks, after the
planned efficacy analysis found a lower than expected virologic response in the raltegravir arm, adding to the potentiallimitation to the study.
The SPIRALstudyhad a 48-weekfollow-up periodand
evaluatedswitchingfrom any ritonavir-boosted PI regimen
to raltegravir." Inclusion criteria in the SPIRAL study required studyparticipants to haveHIV-I RNA concentrations
<50 copies/mL for the previous 6 months. The results conflicted withthe results of the SWITCHMRK 1 and 2 studies,
in thatnoninferiority of raltegravir was demonstrated withthe
ritonavir-boosted PI regimens. The longerduration of viral
suppression required by the SPIRALstudymay explain the
inconsistent fmdings. 56,61 Longer duration of virologic suppression is associated with a decreased riskof virologic failure.56,61,62 It is important for clinicians to obtainbackground
information, including duration of virologic suppression and
pastresistance, before switching therapies.5S-57,61,62
The DHHS guidelines recommend caution when
switching the therapy of an ARV-experienced patientfrom
a boosted PI to raltegravir, stressing the maintenanceof a
fully active OBT.2 The same caution should be employed
in a patient with suspected or documented NRTI resistance.

Adverse Drug Events
Based on compileddata from the Markowitz et al. (Protocol004) and Gatellet al, (Protocol 005) studies,the most
common adverse effects (>5% incidence) associated with
raltegravir are gastrointestinal-related effects, headache, and
dizziness,which are generallytransient,self-limiting, and
mild-to-moderate in severity.9.10,14,63 There was no association betweenthe dose and the frequency of adverse events,
and no dose-related toxicities occurred. Markowitz et al.
found that subjects receiving raltegravir had minimal
changes in lipid levels,including totalcholesterol and lowdensity lipoprotein cholesterol, but lipidswere significantly
increased in the efavirenzgroup (p < OJXH and p < 0.016,
respectivelyj.v Similarly,other trials have displayed only
modest effects on lipids with the use of raltegravir.ve' In
November 2011,the "Warnings and Precautions" section of
the raltegravir product information was updated to report
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severe cases of Stevens-Johnson syndrome and toxic epidermal necrolysis occurring with raltegravir therapy, advising that caution be used in patientswho develop hypersensitivity reactions. Elevations in creatine kinase have been
associated with raltegravir therapy, and case reports of myopathies and rhabdomyolysis with raltegravir have also
been documented.ll,s3,6S.67 In HIV-l infected patients with
hepatitis B and/or hepatitis C coinfection, raltegravir remainsefficacious againstHIV-l and is generally well-tolerated.68 Although these adverse effects are rare, it is important to monitorcreatine kinase in symptomaticpatientsreceivingraltegravir therapy. The favorable toxicity profileof
raltegravir makes it a valuable treatmentoption for patients
intolerant to otherclassesof ART.

Drug Interactions
Raltegravir is eliminated primarily by glucuronidation
via UGTtAl with no effect on the cytochrome P450 pathway; thus, drug interactions are minimal." Rifampin,a potent inducer of UGTtAl , given concomitantly with raltegravir led to a significant decrease in raltegravir AUC by
40%, maximum concentration (Cmax) by 38%, and Cu by
61%.'0A dose increaseof raltegravir to 800 mg twice daily
is recommended when used with rifampin.v" Rifabutin, a
rifamycin antimicrobial with similar activity to rifampin,
does not significantly alter raltegravir pharmacokinetics
and does not require dose adjustments, making it the preferred rifamycin." When atazanavir 100 mg, a potent
UGTIAI inhibitor, was administered with ritonavir 100
mg and raltegravir 400 mg twice daily, the Cmax ' C u, and
l2-hour AUC of raltegravirwere increasedby 37%,49%,
and 32%, respectively," The increased raltegravir plasma
concentrations are not thoughtto be clinically relevant.72•73
Tenofovir is not a potent inhibitor and inducer of cytochrome P450or UGTtAl enzymes, but unexplained clinical interactions with tenofovir and other ARThave been observed, and, therefore, evaluating the potential interaction between tenofovir and raltegravir was of interest. When
. raltegravir400 mg twice daily and tenofovir 300 mg once
daily were coadministered, the l2-hour AUC of raltegravir
increasedby 49% and Cmax by 64%.74 As recommendedin
the DHHSguidelines, the combination can be givenwithout
doseadjustments.2.74
When tipranavir 509 mg twice daily, an inducer of
UGTtAl, was given with ritonavir200 mg twicedaily and
raltegravir 400 mg twice daily, the C u of raltegravir decreased by 45%, and a minimal decrease was seen in the
AUC by 24% and Cmax by 18%.'5 However,no dosage adjustments are necessary, as favorable efficacy data were
observedin the BENCHMRK 1 and 2 trialS.8,s3
In the ACTG A5262 study, darunavir C u was within
range based on previous pharmacokinetic studies,suggesting that the increased virologic failure was not related to a

drug-drug interaction." Another study found that raltegravir with darunavir plus ritonavir did not affect darunavir,raltegravir, or ritonavir pharmacokinetics," However, in
a small, pharmacokinetic substudy of the EASIER-ANRS
study evaluating raltegravir with darunavir 600 mg twice
daily plus ritonavir 100 mg twice daily, the Cmax and 9hour AUC of darunavir were decreased by 33% and 27%,
respectively." No virologic failure was observed up to 48
weeks after initiation of therapy.54,60." Fabbiani et al. found
darunavir concentrations to be decreased when administered with raltegravir, but the effect on virologic efficacy
was uncertain." Clinicians should use caution when considering initiatingraltegravir with darunavir plus ritonavir
for initial therapy because it is unclear whether the pharmacokinetic interaction is of clinicalsignificance.
Etravirine, an inducer of UGTlAl, reduced raltegravir
Cu by 34% when given concomitantly in healthy volunteers." Poor virologic control has been observed when
etravirine and raltegravir are coadministered, with 2 of 4
subjects having a raltegravir Cu below the IC95 for HIV1.79 Increasing the total daily raltegravir dose to 1200
mg/day may be necessary to prevent resistance when administering it with etravirine/"
Raltegravir displays pH-dependent solubility, creating potential interactions with drugs that increase the pH of the
stomach. In subjects not infected with HIV-l who were taking raltegravirand omeprazole,there was a 3- to 4-fold increasein the AUC and Cmax of raltegravir, witha minoreffect
on CU •81However, the half-life of raltegravir remained minimallyaffected, suggesting that omeprazole has no significant
effect on the metabolism, excretion, or efficacy of raltegravir.
Increases in AUC are also seen with histamine (H2)-antagonists,but not with antacids.8~
If usingproton pumpinhibitors
or Hj-antagonists with raltegravir, dose adjustments are not
required.' Withconcomitant administration of an antacid, the
peak concentrations of raltegravir occurred 2 hoursfaster and
C u was significantly lower (p < 0.00(1) due to raltegravir
chelation with multivalent cations." Virologic failure has
been suggested with concomitant administration of raltegravirand calcium-containing products," Routinemonitoring of HIV-l RNA and CD4 count is recommended in patientstakingraltegravir and otheragentswiththe potential to
decrease the efficacy of raltegravir, such as multivalent
cations. Clinicians should strongly consider avoiding concomitant use whenpossible and separate administration times
whenuse of raltegravir withmultivalent cations is indicatedf'

Drug Resistance
Viral resistance to raltegravir results from mutations
within the integrase protein coding sequence, including
mutations N155H, Q148HIRIK, and Y143/R/CIH.84,85 Secondary mutations at position E92 for N155 or Y143, position T97 for Yl43, and positionGl40 for Q148 are associ-
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ated with an increase in raltegravir resistance and restoring
viral fitness," When the mutations Q148H and G140S are
together, a highlyresistant viral strainexistswith a replication profile similar to that ofthe wild type," Wirden et al.
found that subjects with mutations involving the 2 principal resistance pathways (N155 and Q148) displayed no
residual ARV activity when continuing raltegravir therapy.87 Clinicians shouldconsiderthe possibility of these mutations prior to initiating raltegravir therapy, as they have a
profound impacton the success of therapy.
The emergence of resistance to raltegravir has been seen
as early as 1 month after treatment initiation in raltegravirnai've subjects," Ceccherini-Silberstein et al. foundthat primary and secondary INSTI-associated mutations are absent
or extremely rare in subjects who have never received an
INSTI,51 A separate assay is required to detectmutations in
the HIV-l integrase gene," Preexisting raltegravir resistance
found by genotypic and phenotypic testingis rare in ARVnaivesubjects.90,91 However, as INSTIusebecomes common
practice, the incidence of resistance in the population will increase, including resistance in ARV-nai've patients.

New Integrase Strand Transfer Inhibitors
Resistance to current ART and the lack of once daily
regimens warrant the developmentof new agents, including alternative INSTIs. Elvitegravir, a second-generation INSTI,is beingevaluated in ARV-experienced and ARV-nai've
subjects.92,93 In ARV-experienced subjects withOBT including ritonavir and a secondagentof choice,elvitegravir once
daily demonstrated noninferiority to raltegravir twicedaily (p
= 0.001), displaying similarsafetyprofiles." By inhibiting
CYP3A4 metabolism with ritonavir,the concentrations of
elvitegravir increased 20-foldand reduced HIV-l RNA by a
meanof 1.9110g10copies/mL.16,17 Elvitegravir is co-formulated withcobicistat and tenofovir/emtricitabine in a oncedaily
formulation known as QUAD.18Cobicistat lacksanti-HIV-l
activity but increases e1vitegravir concentrations by
CYP3A4-mediated inhibition, mechanistically similarto ritonavir boosting. In ARV-nai've subjects, QUADdemonstrated noninferiority to both efavirenzltenofovir/emtricitabine
and atazanavir plusritonavir andtenofovir/emtricitabine regimens,providing an alternative to NNRTI andritonavir-boosted regimensP'" Once elvitegravir is FDA approved, its use
will be reserved for ARV-nai've or ARV-experienced patients
with no documented resistance to raltegravir, as both elvitegravir andraltegravir havesimilar resistance profiles.15,96
Dolutegravir, an investigational second-generation INSTI,
has a terminal half-life ranging from 13 to 15 hours, with
significantly slower dissociationfrom the integrase DNA
complexes than raltegravir or elvitegravir."?' Dolutegravir
is dosed at 50 mg once daily in ARV-na'ive patients,but in
ARV-experienced patients with Q148+ mutations,dolutegravir 50 mg twice daily must be used due to diminished
theannals.com

activity observed in such patients." Dolutegravir has
shown significant antiviral activity againstHIV-l with raltegravir and elvitegravir integrase mutations, making dolutegravira promisingtherapy for patients with resistance
to raltegravir," Small increases in serum creatinine have
been observed with both dolutegravir and cobicistat, independentof renal function.93,98,99 The once daily formulation
of new INSTIs may contribute to improved adherence,
leadingto decreased INSTIresistance.
Other INSTIs arecurrently beingdeveloped, suchas MK0536 and BI 224436.100,101 MK-0536 has demonstrated efficacy against HIV-l integrase carrying the 3 main raltegravir
resistance mutations: N155H,Y143R,and to a lesserdegree
GI40S-QI48H.lOO BI 224436displays no cross-resistance to
all other approved ART, including other INSTIs.lol Upcoming INSTIs will provide valuable therapy options for both
ARV-miive andARV-experienced HIV-l patients.

Summary
The novel INSTI raltegravir has demonstrated potent
and durable activity againstHIV-l, while maintaining a favorable safety profile. Raltegravir with tenofovir/emtricitabine or abacavir/larnivudine provides an effective therapeuticoptionfor initialART. In ARV-experienced patients,
raltegravir with OBT provides an alternative regimen for
patients with limited remaining treatment options. The
benefits of raltegravirin patients switching from a PI or a
fusion inhibitorinclude fewer adverse drug effects and an
improvedhealth-related qualityof life. Raltegravir may be
a viable treatment option for patients with a contraindication or intolerance to other ART, but its use may be limited
by twicedailydosing. The majorrole of raltegravir was being the first of its class, but as the future once daily INSTIs
come to market, the place of raltegravir in HIV-l therapy
may be obscured. Clinicians should consider all patientspecificdata to determine whether the use of raltegraviris
beneficial for each patient.
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RoleofRaltegravir in HlV·J Management
EXTRACfO

El regimenbasadoen nucle6tido de raltegravir con
tenofovir/emtricitabina proveeuna terapiade prirnera lineaefectiva. Sin
embargo,los regfmenes sin nucle6tido no aparentan ser favorables en
pacientes que no han recibido ARVy debenreservarse para pacientes
con opciones de tratamiento limitadas. Raltegravir utilizado con terapias
adyuvantes optimizadas, proveeun regimenalternopara pacientes
experimentados en el uso de ARY. Esta revisi6n describe la informaci6n
in vitroe in vivodisponible de la potenciade raltegravir, definidacomo
la habilidad de lograruna cargaviral no-detectable, y de su perfilde
seguridad, asfcomo una comparaci6n con terapias de VIH-l estandares,
CONCLUSION: Raltegravir ha demostrado una actividad antirretroviral
potentecontraVIH-l tantoen pacientes que no han recibidoARVcomo
en pacientes experimentados en el usa de ARV, con los beneficios de un
perfilde efectosadversos favorable y un minimade interacciones con
otrosfarmacos. Raltegravir de utilizarse 2 vecesal dia ya que su uso una
vez al dfademuestra una reducci6n en la eficaciavirol6gica comparada
con la dosis 2 vecesal ilia.Sin embargo,el continuodesarrolIo de
nuevosinhibidores de transferencia de la fibrade integrasa podria
proveerregfmenes potentes para uso una vez al dfa.
SINTESIS:

El Papel de Raltegravir en el Manejo de IVH-l
KEERokas, PB Bookstaver, CL Shamroe, SS Sutton, VEMillisor, JE
Bryant, y SB Weissman
Ann Pharmacother 2012;46:578-89.

Revisarla literatura relacionada al uso de raltegravir en el
tratamiento del virusde inmunodeficiencia humanatipo 1 (IVH-l) en
pacientes que han recibidoantirretrovirales (ARV) y en aquelIos que no
han recibido ARV.
FUENTES DE INFORMACI6N: Se realiz6una busquedaen PubMedde
informaci6n publicada hastanoviembre 2011 utilizando los terminosde
busqueda"raltegravir", "MK-0518", e "inhibidorde transferencia de
fibra de integrasa". Ademasse busc6 informaci6n no publicada
incluyendo International Pharmaceutical Abstracts de la Sociedad
Americana de Enfermedades Infecciosas, la Conferencia de Retroviruses
e Infecciones Oportunistas,laSociedadinternacional de SIDA y la
Conferencia Interciencia de Agentes Antimicrobiales y Quimioterapia
utilizando los mismosterminos de biisqueda.
OBJETIVO:

SELECCI6N DE FUENTES DE INFORMACI6N Y METODO DE EXTRACCI6N DE

Traducido par Giselle Rivera-Miranda

Se utilizaron estudios in vitroe in vivo,fase II, fase III y
post-mercadeo disponibles en inglesque evaluaban regfmenes
antirretrovirales que contenfan raltegravir parael tratamiento de
infecci6n por VIH-l en pacientes que han recibido ARVy en aquelIos
que no han recibidoARV. Tambien se incluyeron estudios que
evaluaban la farmacocinetica y farrnacodinamica de raltegravir.
INFORMACI6N:
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